Payment overview · 2025
General Payments
$190.64
9 reported records · 7 companies
Healthcare provider profile · identity verified
Vance G Moore, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · OXFORD, AL · NPI 1629074885
Verified facts
What the public records show
CMS Open Payments records show Vance G Moore, M.D. received $190.64 in general payments during 2025 across 9 reported records.
Novo Nordisk Inc accounted for 36.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nexium by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 270 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $69.49 | 36.5% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $26.36 | 13.8% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.88 | 11.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $21.85 | 11.5% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $20.40 | 10.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.50 | 8.1% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $15.16 | 8.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $190.64 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $69.49 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $26.36 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $21.88 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $21.85 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $20.40 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $20.40 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.50 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $15.16 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 68 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
68 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
270 | 47 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 633 | 132 |
| Atorvastatin Calcium | Atorvastatin Calcium | 526 | 133 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 499 | 111 |
| Pantoprazole Sodium | Pantoprazole Sodium | 439 | 120 |
| Omeprazole | Omeprazole | 430 | 98 |
| Amlodipine Besylate | Amlodipine Besylate | 419 | 103 |
| Hydrochlorothiazide | Hydrochlorothiazide | 337 | 75 |
| Alprazolam | Alprazolam | 330 | 52 |
| Lisinopril | Lisinopril | 320 | 80 |
| Simvastatin | Simvastatin | 310 | 67 |
| Ozempic | Semaglutide | 270 | 47 |
| Famotidine | Famotidine | 265 | 55 |
| Losartan Potassium | Losartan Potassium | 256 | 65 |
| Pravastatin Sodium | Pravastatin Sodium | 254 | 60 |
| Metformin Hcl Er | Metformin Hcl | 248 | 61 |
| Gabapentin | Gabapentin | 244 | 56 |
| Allopurinol | Allopurinol | 211 | 46 |
| Clonazepam | Clonazepam | 203 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 203 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 190 | 42 |
| Potassium Chloride | Potassium Chloride | 188 | 43 |
| Montelukast Sodium | Montelukast Sodium | 186 | 52 |
| Meloxicam | Meloxicam | 183 | 39 |
| Metformin Hcl | Metformin Hcl | 183 | 47 |
| Tramadol Hcl | Tramadol Hcl | 183 | 37 |
| Sertraline Hcl | Sertraline Hcl | 175 | 50 |
| Carvedilol | Carvedilol | 148 | 37 |
| Furosemide | Furosemide | 128 | 40 |
| Glimepiride | Glimepiride | 123 | 34 |
| Doxycycline Hyclate | Doxycycline Hyclate | 121 | 89 |
| Celecoxib | Celecoxib | 120 | 29 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 117 | 26 |
| Trazodone Hcl | Trazodone Hcl | 112 | 29 |
| Mounjaro | Tirzepatide | 110 | 16 |
| Metoprolol Succinate | Metoprolol Succinate | 105 | 31 |
| Lorazepam | Lorazepam | 104 | 20 |
| Pregabalin | Pregabalin | 103 | 30 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 103 | 48 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 101 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 99 | 31 |
| Temazepam | Temazepam | 99 | 14 |
| Tresiba Flextouch U-200 | Insulin Degludec | 98 | 21 |
| Prednisone | Prednisone | 96 | 68 |
| Phenobarbital | Phenobarbital | 95 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 92 | 16 |
| Atenolol | Atenolol | 91 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 83 | 16 |
| Trulicity | Dulaglutide | 80 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 77 | suppressed |
| Nystatin | Nystatin | 77 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 76 | 18 |
| Eliquis | Apixaban | 74 | 20 |
| Azithromycin | Azithromycin | 73 | 63 |
| Baclofen | Baclofen | 73 | 11 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 71 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 70 | 18 |
| Farxiga | Dapagliflozin Propanediol | 68 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 67 | 47 |
| Methocarbamol | Methocarbamol | 67 | 18 |
| Spironolactone | Spironolactone | 67 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 66 | 22 |
| Glipizide Er | Glipizide | 66 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 66 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 64 | 19 |
| Topiramate | Topiramate | 62 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 61 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 61 | 12 |
| Meclizine Hcl | Meclizine Hcl | 60 | 21 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 60 | 11 |
| Glipizide | Glipizide | 59 | 17 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 58 | 40 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 57 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 56 | 18 |
| Bupropion Xl | Bupropion Hcl | 55 | 12 |
| Synthroid | Levothyroxine Sodium | 55 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 53 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 53 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 52 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 52 | 13 |
| Amoxicillin | Amoxicillin | 51 | 35 |
| Citalopram Hbr | Citalopram Hydrobromide | 51 | 15 |
| Ondansetron Odt | Ondansetron | 51 | 32 |
| Mirtazapine | Mirtazapine | 46 | suppressed |
| Glyburide | Glyburide | 45 | 14 |
| Fluconazole | Fluconazole | 44 | 29 |
| Sucralfate | Sucralfate | 44 | suppressed |
| Ibuprofen | Ibuprofen | 43 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 43 | 12 |
| Warfarin Sodium | Warfarin Sodium | 43 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 42 | 18 |
| Ezetimibe | Ezetimibe | 42 | 13 |
| Valsartan | Valsartan | 42 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 41 | suppressed |
| Xarelto | Rivaroxaban | 40 | suppressed |
| Lansoprazole | Lansoprazole | 39 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 38 | 19 |
| Mupirocin | Mupirocin | 37 | 26 |
| Paxlovid | Nirmatrelvir/Ritonavir | 37 | 37 |
| Finasteride | Finasteride | 36 | suppressed |
| Jardiance | Empagliflozin | 36 | suppressed |
| Ramipril | Ramipril | 36 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 35 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 34 | 12 |
| Estradiol | Estradiol | 33 | suppressed |
| Carbamazepine | Carbamazepine | 32 | suppressed |
| Verapamil Er | Verapamil Hcl | 32 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 31 | suppressed |
| Trimethoprim | Trimethoprim | 31 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 30 | suppressed |
| Lamotrigine | Lamotrigine | 30 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 12 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 28 | suppressed |
| Eszopiclone | Eszopiclone | 28 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Chlorthalidone | Chlorthalidone | 27 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 27 | suppressed |
| Acebutolol Hcl | Acebutolol Hcl | 24 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 24 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 24 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 24 | 24 |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Bumetanide | Bumetanide | 23 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 23 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 23 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 23 | suppressed |
| Lidocaine | Lidocaine | 22 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Invokana | Canagliflozin | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Methimazole | Methimazole | 20 | suppressed |
| Methylprednisolone | Methylprednisolone | 20 | 19 |
| Cefuroxime | Cefuroxime Axetil | 19 | 19 |
| Testosterone | Testosterone | 19 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 18 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 18 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Nabumetone | Nabumetone | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 14 |
| Cephalexin | Cephalexin | 16 | 15 |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Dulera | Mometasone/Formoterol | 16 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Premarin | Estrogens, Conjugated | 15 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Azathioprine | Azathioprine | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | suppressed |
| Mesalamine | Mesalamine | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Neurontin | Gabapentin | 13 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 13 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Trospium Chloride | Trospium Chloride | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 12 | suppressed |
| Desloratadine | Desloratadine | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 12 | suppressed |
| Oxazepam | Oxazepam | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Cefdinir | Cefdinir | 11 | 11 |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Hydrocodone-Ibuprofen | Hydrocodone/Ibuprofen | 11 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 11 | suppressed |
| Nexium | Esomeprazole Magnesium | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Sulindac | Sulindac | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $190.64 · 9 records | Novo Nordisk Inc | Cologuard Collection Kit, Dexcom G6 Transmitter, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, GVOKE HYPOPEN, Korlym, Wegovy | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error